Literature DB >> 2373861

Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2.

Y Yamaguchi1, T Suda, H Shiozaki, Y Miura, Y Hitoshi, A Tominaga, K Takatsu, T Kasahara.   

Abstract

We recently demonstrated in vivo that IL-5 was an important mediator of eosinophilia in mice with parasite infections. In this study, we examined whether or not IL-5 was actually responsible for the eosinophilia induced by injection of human rIL-2. Mice administered hIL-2 developed eosinophilia during the course of the series of injections. This eosinophilia could be suppressed by a single injection of mAb against murine IL-5. The number of eosinophilic precursors increased more in the spleen cells of the IL-2-treated mice in comparison to the control mice, although in bone marrow precursors showed little change. Similarly, the number of granulocytic precursors increased markedly in the spleen cells of IL-2-treated mice. In vitro polymerase chain reaction amplification of cDNA subfragments corresponding to IL-5 mRNA (reverse transcription-polymerase chain reaction), followed by Southern blot analysis, revealed enhancement of IL-5 mRNA expression in spleen cells 3 days after starting the human IL-2 injections. We also observed enhanced murine IL-5 mRNA expression in spleen cells stimulated with IL-2 in vitro. The level of murine IL-5 mRNA expression by IL-2-stimulated spleen cells from normal mice increased at 24 h, reached a plateau after 48 h, and decreased again within 72 h of starting culture. These results indicate that the eosinophilia induced by IL-2 in vivo is presumably mediated by IL-5 released from IL-2-stimulated lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373861

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.

Authors:  S Arinaga; N Karimine; K Takamuku; S Nanbara; H Inoue; R Abe; D Watanabe; H Matsuoka; H Ueo; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Interleukin-12 modulates T-cell responses to microfilariae but fails to abrogate interleukin-5-dependent immunity in a mouse model of onchocerciasis.

Authors:  P J Hogarth; A E Bianco
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

3.  L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.

Authors:  H Barth; R Klein; P A Berg
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 4.  Eosinophils and Lung Cancer: From Bench to Bedside.

Authors:  Anne Sibille; Jean-Louis Corhay; Renaud Louis; Vincent Ninane; Guy Jerusalem; Bernard Duysinx
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

5.  Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study.

Authors:  A Lindemann; P Brossart; K Höffken; M Flasshove; D Voliotis; V Diehl; G Hecker; H Wagner; R Mertelsmann
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

6.  Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.

Authors:  S Arinaga; N Karimine; M Adachi; H Inoue; S Nanbara; T Asoh; H Ueo; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

7.  Interleukin-5 induces tumor suppression by peritoneal exudate cells in mice.

Authors:  Y Nakashima; S Mita; K Takatsu; M Ogawa
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

8.  Immunity to Trichinella spiralis infection in vitamin A-deficient mice.

Authors:  J A Carman; L Pond; F Nashold; D L Wassom; C E Hayes
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

9.  Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.

Authors:  D J Deehan; S D Heys; W Simpson; R Herriot; J Broom; O Eremin
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

10.  Regulatory role of pro-Th1 and pro-Th2 cytokines in modulating the activity of Th1 and Th2 cells when B cell and macrophages are used as antigen presenting cells.

Authors:  Vinod Singh; Javed N Agrewala
Journal:  BMC Immunol       Date:  2006-08-07       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.